ArriVent BioPharma (AVBP) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$1.05

Estimate

-$0.98

Surprise

-6.7%

Score today

5.4/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

ArriVent BioPharma (AVBP) reported a wider loss than forecast — diluted EPS of -$1.05 against the -$0.98 estimate (a 6.7% shortfall).

• Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40 — benzinga, 2026-08-13
• Guggenheim Reiterates Buy on ArriVent BioPharma, Maintains $45 Price Target — benzinga, 2026-08-13
• BTIG Reiterates Buy on ArriVent BioPharma, Maintains $42 Price Target — benzinga, 2026-08-13

TrendMatrix currently rates AVBP Sell at 5.4/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -6.7% surprise compares with a -3.1% four-quarter average. Next scheduled report: 2026-11-16.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$30.83

Price target

$38.89

Stop

$28.67

Upside to target

+26.1%

Reward-to-risk

2.9:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.53B

P/E (fwd)

-8.2

52-week range

$17.00–$35.83

Off 52-week high

14.0%

RSI (14)

61

Volume vs avg

0.08×

Score today

5.4/10